| Also known as |
rhuMAb HER2 |
| Blood pressure |
Can cause hypertension |
| Chemical name |
Trastuzumab |
| Dosage (medical) |
Typically 4 mg/kg as a loading dose followed by 2 mg/kg weekly or 6 mg/kg every three weeks |
| Dosage (sports) |
Not applicable |
| Effects |
Reduction in tumor growth, improved survival in breast cancer patients |
| Formula |
C6484H9996N1720O2014S44 |
| Half-life |
Approximately 28 days |
| Hepatotoxicity |
Low |
| Lab Test |
HER2 testing (immunohistochemistry or fluorescence in situ hybridization) |
| Main action |
HER2/neu receptor antagonist |
| Raw Material |
Drostanolone Propionate |
| Side effects |
Fever, nausea, vomiting, infusion reactions, cardiotoxicity |
| Storage conditions |
Store refrigerated at 2-8В°C (36-46В°F) |
| Substance class |
Monoclonal antibody |
| Trade name |
Herceptin |
| Use in sports |
None |
| Water Retention |
Minimal |
| Manufacturer |
DRIADA |
| Packing |
10 amps (1 ml - 100 mg/ml) |
